In this communication, the members of the Porto group (the European Society for Paediatric Gastroenterology, Hepatology and Nutrition [ESPGHAN], inflammatory bowel diseases [IBD] working group) provide the current available evidence regarding vaccination of children and young adolescents with IBD against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our intent is to help provide meaningful answers to the concerns that parents and adolescents may have.

Department of Paediatrics University Hospital Motol Prague Czech Republic

Paediatric Gastroenterology Unit UZ Brussels VUB Brussels Belgium

Zobrazit více v PubMed

https://www.cdc.gov/coronavirus/2019ncov/vaccines/recommendations/adolescents.html . Accessed June 18, 2021.

https://www.ema.europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12–15-eu . Accessed June 18, 2021.

https://www.ema.europa.eu/en/documents/rmp-summary/covid-19-vaccine-janssen-epar-risk-management-plan_en.pdf . Accessed June 18, 2021.

Siegel CA, Melmed GY, Mc Govern D, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut 2021; 70:635–640.

https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised . Accessed June 18, 2021.

Polack FP, Thomas SJ, Kitchin N, et al. Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383:2603–2615.

https://clinicaltrials.gov/ct2/show/NCT04368728 —see phase 2/3. Accessed June 18, 2021.

https://www.ema.europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu . Accessed June 18, 2021.

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html . Accessed June 18, 2021.

Voysey M, Costa Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397:99–111.

Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384:403–416.

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal . Accessed June 18, 2021.

https://clinicaltrials.gov/ct2/show/NCT04551547?term=children%2C+adolescents&cond=covid+19+vaccine&draw=2&rank=5 . Accessed June 18, 2021.

https://clinicaltrials.gov/ct2/show/NCT04796896?cond=covid+vaccine+children&draw=2&rank=2 . Accessed June 18, 2021.

https://clinicaltrials.gov/ct2/results?recrs=&cond=covid+19+vaccine&term=children%2C+adolescents&cntry=&state=&city=&dist =. Accessed June 18, 2021.

https://clinicaltrials.gov/ct2/show/NCT04649151 . Accessed June 18, 2021.

Bronsky J, de Ridder L, Ruemmele FM, et al. Paediatric inflammatory bowel diseases: results from a clinical practice survey. J Pediatr Gastroenterol Nutr 2019; 68:676–683.

Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial. Gut 2020: doi: 10.1136/gutjnl-2020-322339. [Ahead of print]. DOI

Veereman-Wauters G, de Ridder L, Veres G, et al. ESPGHAN IBD Porto Group. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary. J Pediatr Gastroenterol Nutr 2012; 54:830–837.

Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5:851–856.

Jongsma MME, Winter DA, Huynh HQ, et al. Infliximab in young paediatric IBD patients: it is all about the dosing. Eur J Pediatr 2020; 179:1935–1944.

Kennedy NA, Lin S, Goodhand JR, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines preprint. Available at: https://www.medrxiv.org/content/10.1101/2021.03.25.21254335v1 . Accessed June 18, 2021.

Wong SY, Dixon R, Martinez Pazos V, et al. Serologic response to messenger RNA coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies. Gastroenterology 2021; S0016-5085(21)00648-X. [Ahead of print].

Uhlig HH, Charbit-Henrion F, Kotlarz D, et al. Clinical genomics for the diagnosis of monogenic forms of inflammatory bowel disease: a position paper from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2021; 72:456–473.

Bhopal SS, Bagaria S, Olabi B, et al. COVID-19 deaths in children: comparison with all- and other causes and trends in incidence of mortality. Public Health 2020; 188:32–34.

Ciuca IM. COVID-19 in children: an ample review. Risk Manag Healthc Policy 2020; 13:661–669.

Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect 2020; 53:404–412.

Whittaker E, Bamford A, Kenny J, et al. PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020; 324:259–269.

Phuong LK, Bonetto C, Buttery J, et al. Collaboration Kawasaki Disease (KD) Working Group. Kawasaki disease and immunisation: a systematic review. Vaccine 2017; 35:1770–1779.

Ludvigsson JF, Axelrad J, Halfvarson J, et al. Inflammatory bowel disease and risk of severe COVID-19: a nationwide population-based cohort study in Sweden. United European Gastroenterol J 2021; 9:177–192.

Derikx LAAP, Lantinga MA, de Jong DJ, et al. Clinical outcomes of COVID-19 in patients with inflammatory bowel disease: a nationwide cohort study. J Crohns Colitis 2021; 15:529–539.

Attauabi M, Poulsen A, Theede K, et al. Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease—a Danish prospective population-based cohort study. J Crohns Colitis 2020; 15:540–550.

Brenner EJ, Pigneur B, Focht G, et al. Benign evolution of SARS-Cov2 infections in children with inflammatory bowel disease: results from two international databases. Clin Gastroenterol Hepatol 2021; 19:394.e5–396.e5.

Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617. 2 and B. 1. 351 by BNT162b2 vaccination. Lancet 2021; 397:2331–2333.

Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease